Identification and external validation of the optimal FIB-4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings.

ABSTRACT:

Background

With the initially defined thresholds, the most widely used serum biomarkers for staging liver fibrosis (ie, APRI and FIB-4 scores) proved to be ineffective among patients with chronic hepatitis B virus infection (CHB). Whether optimizing the FIB-4 and APRI thresholds could improve their diagnostic accuracy requires further research.

Methods

Using data of treat-naïve CHB patients from three tertiary hospitals, we explored the optimal FIB-4 and APRI thresholds to rule in liver fibrosis accurately. Subsequently, we validated the applicability of the newly defined thresholds to the CHB patients from another two tertiary hospitals.

Results

The fibrosis stages between discovery cohort (n = 433) and the external validation cohort (n = 568) were statistically diff

SUBMITTER: Liu K 

PROVIDER: S-EPMC7891512 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature